US Bancorp DE Sells 700 Shares of Maximus, Inc. (NYSE:MMS)

US Bancorp DE trimmed its position in Maximus, Inc. (NYSE:MMS) by 10.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 6,258 shares of the health services provider’s stock after selling 700 shares during the period. US Bancorp DE’s holdings in Maximus were worth $467,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the stock. Atria Investments Inc bought a new stake in Maximus in the 3rd quarter worth approximately $244,000. Covestor Ltd increased its holdings in shares of Maximus by 913.0% in the third quarter. Covestor Ltd now owns 1,246 shares of the health services provider’s stock valued at $116,000 after purchasing an additional 1,123 shares during the period. Crossmark Global Holdings Inc. boosted its stake in shares of Maximus by 9.8% in the third quarter. Crossmark Global Holdings Inc. now owns 4,152 shares of the health services provider’s stock worth $387,000 after buying an additional 369 shares during the last quarter. Versor Investments LP boosted its position in Maximus by 213.5% during the third quarter. Versor Investments LP now owns 8,500 shares of the health services provider’s stock worth $792,000 after purchasing an additional 5,789 shares in the last quarter. Finally, Entropy Technologies LP acquired a new position in shares of Maximus during the third quarter valued at approximately $214,000. 97.21% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Maximus news, insider Ilene R. Baylinson sold 14,500 shares of the firm’s stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $68.14, for a total value of $988,030.00. Following the sale, the insider now owns 2,512 shares in the company, valued at approximately $171,167.68. This trade represents a 85.23 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Bruce Caswell bought 3,500 shares of the company’s stock in a transaction that occurred on Tuesday, December 17th. The shares were purchased at an average cost of $70.64 per share, for a total transaction of $247,240.00. Following the acquisition, the chief executive officer now owns 275,929 shares of the company’s stock, valued at $19,491,624.56. This represents a 1.28 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.60% of the stock is owned by company insiders.

Maximus Price Performance

MMS stock opened at $66.45 on Thursday. The stock’s 50 day moving average price is $72.56 and its 200 day moving average price is $79.84. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.72 and a current ratio of 1.72. The firm has a market cap of $3.76 billion, a P/E ratio of 14.29 and a beta of 0.71. Maximus, Inc. has a 1 year low of $63.77 and a 1 year high of $93.97.

Maximus (NYSE:MMS) last announced its quarterly earnings results on Thursday, February 6th. The health services provider reported $1.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.39 by $0.22. Maximus had a return on equity of 21.95% and a net margin of 5.28%. On average, sell-side analysts expect that Maximus, Inc. will post 6.15 earnings per share for the current fiscal year.

Maximus Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, February 28th. Stockholders of record on Saturday, February 15th were given a dividend of $0.30 per share. The ex-dividend date of this dividend was Friday, February 14th. This represents a $1.20 annualized dividend and a dividend yield of 1.81%. Maximus’s payout ratio is 25.81%.

Wall Street Analyst Weigh In

MMS has been the subject of several recent research reports. Raymond James raised Maximus from a “market perform” rating to an “outperform” rating and set a $90.00 price target for the company in a report on Thursday, January 2nd. StockNews.com cut Maximus from a “buy” rating to a “hold” rating in a research report on Friday, February 14th.

Maximus Profile

Maximus, Inc operates as a provider of government services in the United States and internationally. It operates through three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The U.S. Services segment offers program eligibility support and enrollment; centralized multilingual customer contact centers, multichannel, and digital self-service options for enrollment; application assistance and independent health plan choice counseling; beneficiary outreach, education, eligibility, enrollment, and redeterminations; and person-centered independent disability, long-term sick, and other health assessments.